Latest Regulatory Milestones News

Paladin Energy reports a 33% production surge at its Langer Heinrich Mine alongside a key environmental milestone for its Canadian project and announces a new CEO appointment. The company outlines strong FY2026 guidance amid ongoing operational ramp-up.

Invex Therapeutics has broadened its collaboration with Tessara Therapeutics to explore Exenatide’s potential in Alzheimer’s disease, while successfully renewing key orphan drug designations in Europe and the US.

Inhalerx Limited has drawn $247,000 from a $38.5 million funding facility to advance clinical trials for its IRX-211 and IRX-616a drug candidates, reporting positive operating cash flow for the quarter ending June 2025.

InhaleRx Limited has secured key ethics approvals and initiated manufacturing for its inhaled drug candidates targeting breakthrough cancer pain and panic disorder, supported by a $38.5 million funding facility to accelerate development.

Argosy Minerals Limited has launched a $2 million placement accompanied by an offer of up to 40 million options, aiming to bolster development and feasibility efforts at its Rincon Lithium Project in the USA.

EVE Health Group has secured regulatory approval enabling prescription access for its lead products Libbo and Dyspro in Australia, setting the stage for a commercial rollout before the end of 2025.

Elixir Energy has advanced its strategic plan in Queensland’s Taroom Trough, appointing a new COO, initiating a major cost reduction, and preparing to drill key exploration and appraisal wells that could unlock significant gas resources.

Lumos Diagnostics reported a 12% revenue increase for FY25 and inked a landmark US$317 million exclusive distribution deal for its FebriDx test, while advancing its FDA CLIA waiver application.

Macro Metals Limited is poised to resume trading on the ASX from July 18, 2025, following a key Supreme Court decision. The lifting of its trading suspension marks a significant regulatory milestone for the mining company.

Lumos Diagnostics has locked in a A$5 million secured loan facility to support working capital as it advances toward FDA CLIA waiver for its FebriDx® test, complementing a landmark US distribution deal.

Lumos Diagnostics has inked a landmark six-year exclusive distribution agreement with PHASE Scientific for its FebriDx® rapid diagnostic test in the US, potentially unlocking nearly half a billion Australian dollars in revenue contingent on FDA approval.

Wia Gold Limited has significantly upgraded its Kokoseb Gold Project resource to 2.93 million ounces, advancing steadily toward a Definitive Feasibility Study targeted for late 2026. The company’s accelerated drilling and strong high-grade results underpin its ambition to become Namibia’s fourth commercial gold mine.